The Natural History of Patients With Pre-Existing and De Novo Inflammatory Bowel Disease After Solid Organ Transplantation: EITOS Study of GETECCU.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bastón-Rey Iria, Rodríguez-Lago Iago, Luque Ana María, Caballol Berta, Soutullo-Castiñeiras Carlos, Bravo Ana, Castaño Andrés, Gros Beatriz, Bernal Lorena, Diz-Lois María Teresa, Alonso-Galán Horacio, Cañete Fiorella, Castro Beatriz, Pérez-Galindo Pablo, González-Muñoza Carlos, El Hajra Ismael, Martínez-Montiel Pilar, Alonso-Abreu Inmaculada, Mesonero Francisco, González-Vivo María, Peries Laia, Martín-Arranz Eduardo, Abril Carlos, Marín-Jiménez Ignacio, Baltar Ruth, Vicuña Miren, Moreno Nadia, Brunet Eduard, Rubín de Célix Cristina, Fajardo Ingrid, Cruz Noelia, Calvino-Suárez Cristina, Rojas-Feria María, Fernández-Clotet Agnes, Gimeno-Torres Marta, Nieto-Garcia Laura, de la Iglesia Daniel, Zabana Yamile, Suárez-Ferrer Cristina, Barreiro de Acosta Manuel
Аннотация
METHODS: This was a retrospective, multicenter study that included patients with pre-existing IBD at the time of SOT and patients with de novo IBD after SOT. The primary outcome was IBD progression, defined by escalation of medical treatment, surgical therapy, or hospitalization due to refractory IBD. Risk factors were identified using multivariate Cox proportional hazard analysis.
RESULTS: A total of 177 patients (106 pre-existing IBD and 71 de novo IBD) were included. Most patients with pre-existing IBD (92.5%) were in remission before SOT. During follow-up, 32% of patients with pre-existing IBD had disease progression, with a median time between SOT and IBD progression of 2.2 (interquartile range, 1.3-4.6) years. In the de novo cohort, 55% of patients had disease progression with a median time to flare of 1.9 (interquartile range, 0.8-3.9) years after diagnosis. In the pre-existing IBD cohort, active IBD at the time of SOT (hazard ratio, 1.80; 95% confidence interval, 1.14-2.84; P = .012) and the presence of extraintestinal manifestations (hazard ratio, 3.10; 95% confidence interval, 1.47-6.54; P = .003) were predictive factors for IBD progression.
CONCLUSIONS: One-third of patients with pre-existing IBD and about half of patients with de novo IBD have disease progression after SOT. Active IBD at the time of SOT and the presence of extraintestinal manifestations were identified as risk factors for IBD progression.